Abstract
The rising incidence of thyroid cancer observed in the last few decades requires an improvement in diagnostic tools and management techniques for patients with thyroid nodules. The aim of this study was to assess serum concentrations of IGF-1 and IGF-1R in patients diagnosed with thyroid cancers. 36 patients diagnosed with papillary thyroid cancer (PTC), 11 subjects with follicular thyroid cancer (FTC), 9 patients with anaplastic thyroid cancer (ATC) and 19 subjects with multinodular nontoxic goiter (MNG) were enrolled to the study. The control group (CG) consisted of 20 healthy volunteers. Blood samples were collected one day before surgery. Serum IGF-1 and IGF-1R concentrations were measured using specific ELISA methods. Significantly higher concentrations of IGF-1 were found in patients with PTC as compared with controls but not that obtained from subjects diagnosed with MNG. The concentration of IGF-1R was significantly elevated in subjects with PTC and ATC as compared with healthy volunteers. Similarly, patients diagnosed with PTC or ATC presented significantly higher serum concentration of IGF-1R in comparison to the MNG group. Our results show that the IGF-1 - IGF-1R axis plays a significant role in the development of PTC and ATC and imply that serum concentrations of both cytokines may be considered as additional markers for the differentiation of malignancies during the preoperative diagnosis of patients with thyroid gland tumors. These results indicate that IGF-1R serum concentrations allow us to differentiate between MNG and PTC or ATC. Moreover IGF-1R serum values appear to be better predictor of PTC and ATC than IGF-1 concentrations.
Highlights
Thyroid cancer (TC) is the most common endocrine malignancy with a rapidly rising incidence rate that has been observed continuously all over the world over the last few decades[1,2]
The mean Insulin-like growth factor type 1 Receptor (IGF-1R) serum concentration was significantly higher in patients diagnosed with papillary thyroid cancer (PTC) (39.7 ± 3.8 ng/mL) than in healthy volunteers (16.7 ± 3.0 ng/mL; P
The mean insulin-like growth factors (IGFs)-1R serum concentration obtained from patients diagnosed with anaplastic thyroid cancer (ATC) (36.3 ± 8.2 ng/mL) was significantly higher than that observed in controls (16.7 ± 3.0 ng/mL; P
Summary
Thyroid cancer (TC) is the most common endocrine malignancy with a rapidly rising incidence rate that has been observed continuously all over the world over the last few decades[1,2]. According to the National Cancer Institute Surveillance, Epidemiology, and End Results Program, TC accounts for 3.4% of all cancers diagnosed yearly[4] and, in 2030, it is estimated to be the fourth leading cancer diagnosis in United States[5] Much of this rise appears to be the result of progress in diagnostics, e.g. the increased use of thyroid ultrasound, which can detect small thyroid nodules that might not otherwise have been found in the past The aim of this study was to assess serum concentrations of IGF-1 and IGF-1R in patients diagnosed with thyroid cancers. Patients diagnosed with PTC or ATC presented significantly higher serum concentration of IGF-1R in comparison to the MNG group. Our results show that the IGF-1 – IGF-1R axis plays a significant role in the development of PTC and ATC and imply that serum concentrations of both cytokines may be considered as additional markers for the differentiation of malignancies during the preoperative diagnosis of patients with thyroid gland tumors. IGF-1R serum values appear to be better predictor of PTC and ATC than IGF-1 concentrations
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
